Poser, Wolfgang

[["dc.bibliographiccitation.firstpage","273"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","85"],["dc.contributor.author","Sachse-Seeboth, C."],["dc.contributor.author","Pfeil, J."],["dc.contributor.author","Sehrt, D."],["dc.contributor.author","Meineke, I."],["dc.contributor.author","Tzvetkov, M."],["dc.contributor.author","Bruns, E."],["dc.contributor.author","Poser, W."],["dc.contributor.author","Vormfelde, S. V."],["dc.contributor.author","Brockmöller, J."],["dc.date.accessioned","2019-07-09T11:52:51Z"],["dc.date.available","2019-07-09T11:52:51Z"],["dc.date.issued","2008"],["dc.description.abstract","The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9 2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9 3/ 3 homozygotes than in CYP2C9 1/ 1 homozygotes. CYP2C9 3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9 3 variant may influence both the therapeutic and adverse effects of THC."],["dc.identifier.doi","10.1038/clpt.2008.213"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60294"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]